NETHERLANDS - Peakadilly closes series A financing at EUR 14.5m

Peakadilly NV, the predictive protein biomarkers company, has today announced the final close of its series A financing, raising a further EUR 8.5m and bringing the total raised to EUR 14.5m. Investors in the second close of the series A financing were GIMV, Life Science Partners (LSP), who led the series A round, KBC Private Equity, and Baekeland Fonds II, the venture capital fund of the Ghent University Association. LSP alongside Johnson and Johnson Development Corporation were an investor in the EUR 6m first close of this VIB start-up company in March 2006.